Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Research In Brief

This article was originally published in The Gray Sheet

Executive Summary

Five steps to CER success?: Three contributors to high-level discussions on comparative effectiveness research (CER) propose a five-step process toward developing a national CER program in a New England Journal of Medicine article published online Feb. 17. Jordan VanLare of the Department of Health and Human Services, Patrick Conway, executive director of the Federal Coordinating Council for CER, and Harold Cox, co-chair of the Institute of Medicine's Committee on CER Prioritization, suggest first establishing an overall funding strategy. The program should focus on a coordinated portfolio of research on priority topics, infrastructure enhancement, and translation and adoption. Next, it should create an initial list of priority topics and evaluate current knowledge on each, and, with outside input, choose research methods that will fill the evidence gaps for specific topics. Finally, the program should strive for a "balanced portfolio of high-impact research topics" and publicly report on its progress. Last summer, IOM submitted a report to Congress with 100 recommended priorities for federally funded CER (1"The Gray Sheet" July 6, 2009)

You may also be interested in...

Vertebroplasty Shows No More Benefit Than Sham Procedures In Trials

The first two blinded, randomized, placebo-controlled trials of vertebroplasty treatment for spinal fractures suggest that the procedure may have no lasting benefit, researchers report in the Aug. 6 New England Journal of Medicine

Institute Of Medicine Sets Top 100 Comparative Effectiveness Priorities

A June 30 Institute of Medicine 1report to Congress includes dozens of surgical- and device-related topics among a list of 100 recommended priorities for federally-funded comparative effectiveness research

Biohaven’s Oral CGRP Inhibitor Nurtec ODT Approved In The US For Acute Migraine

The fast-dissolving tablet will launch in early March. Its list price is not available but based on pricing for Allergan’s oral anti-CGRP Ubrelvy, ICER has said Biohaven’s rimegepant is likely to be cost-effective.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts